Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Innate Pharma

FREUR
← Allo Screener

Innate Pharma (US:IPHYF) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 3. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'Azienda

Sito Web
innate-pharma.com
Settore
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede Centrale
MARSEILLE, France
Amministratore Delegato
Jonathan E. Dickinson
Dipendenti
120
Fondata
1999
Azioni in Circolazione
111.7 Mln
Flottante
70.45 Mln
Capitalizzazione di Mercato
146.33 Mln EUR
Insider
17.46%
Investitori Istituzionali
10.86%
Settore (SIC)
Biological Products, (No Diagnostic Substances)
Forma Giuridica
K65D
ISIN
FR0010331421
LEI
9695002Y8420ZB8HJE29
FCF
−52.9 Mln EUR
Debito
0
Utili e FCF — per i 12 mesi a 31.12.2025 (l'ultimo rapporto dell'azienda).
Descrizione

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Borse e Ticker

BorsaTickerValutaPrezzoTipo
PA Euronext ParisIPH principaleEUR1.282 -1.54%azioni ordinarie
LSE London Stock Exchange0EVI IOBEUR1.304 +2.27%azioni ordinarie
US USA StocksIPHYF OTCUSD1.5092 -8.53%azioni ordinarie

Prezzo su 3 Mesi

PA:IPH · EUR
US:IPHYF non ha registrato operazioni negli ultimi 3 mesi — il grafico mostra PA:IPH
giorno di rialzo giorno di ribassoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo
pubblicità

Principali Azionisti

DetentoreQuotaAzioniData del Rapporto
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30